Central and Peripheral Adiposity and Iron Absorption

Federal Institute of Technology (ETH) Zurich

Status: Completed

Conditions: Iron-deficiency; Adiposity

Treatments: Other: Stable iron isotopes

Study type: Interventional

Funder types: Other

Identifiers

NCT03642223

FLAB

Details and patient eligibility

About

Adiposity is a state of sub-clinical inflammation, thus hepcidin is increased in adiposity, often leading to iron deficiency in this population group. Central adiposity is generally considered having a greater negative effect on health compared to peripheral adiposity. Whether this can be also seen in hepcidin and thereby in iron absorption is uncertain.

Enrollment: 121 patients

Sex: Female

Ages: 20 to 55 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• either normal-weight (BMI 18-25kg/m2) or overweight/obese (BMI 28-50kg/m2) with either central or peripheral fat deposits based on DEXA

Exclusion criteria

• Iron Supplement or antibiotic intake within 2 weeks before study start
• diagnosed chronic disease or gastrointestinal disorders
• regular use of medication (except contraceptives)
• pregnancy
• lactation
• smoking
• blood donation or surgery within the last 4 months.

Trial design

Primary purpose: Other

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

121 participants in 3 patient groups

normal-weight

Active Comparator group

Treatment:

Other: Stable iron isotopes

peripheral adiposity

Experimental group

Treatment:

Other: Stable iron isotopes

central adiposity

Experimental group

Treatment:

Other: Stable iron isotopes